Previous 10 | Next 10 |
2024-04-02 08:37:57 ET More on Pre-market losers & stocks. Hut 8 Mining Corp. (HUT) Q4 2023 Earnings Call Transcript From Bull To Bear: Recent Events Drove Me To Exit My Position In HUT 8 Hut 8 Post-Merger Comprehensive Thesis: JCapital Research Might Be Right ...
2024-04-02 04:53:23 ET More on Gritstone bio Gritstone bio: Looking For Validation In 2024 Gritstone stock plunges 35% amid Phase 2 data, public offering Gritstone announces proposed public offering Read the full article on Seeking Alpha For further d...
EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced the pricing of an approximately $32.5 million underwritten public offering of its comm...
2024-04-01 16:55:25 ET More on Gritstone bio, Humana, etc. UnitedHealth Group: Buy The Recent Pullback - Long-Term Tailwinds Remain Excellent UnitedHealth Group: Optum To Drive Growth But Watch For Regulatory Risk Humana: This Year's Drop Might Have Created A Buying ...
2024-04-01 16:15:17 ET More on Gritstone bio Gritstone bio: Looking For Validation In 2024 Gritstone to cut 40% of staff due to funding delay, stock plunges 23% Seeking Alpha’s Quant Rating on Gritstone bio Historical earnings data for Gritstone bio ...
EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that it has commenced an underwritten public offering of shares of its common stock (o...
-- Early progression-free survival (PFS) trends favor GRANITE recipients with hazard ratios of 0.82 in the overall population ([95% CI, 0.34-1.67]; 62% censored) and 0.52 (48% relative risk reduction of progression or death with GRANITE vs. control) in a high-risk group, where clinical data are m...
2024-03-28 15:00:00 ET More on the markets Where This Market Is Going (Technical Analysis) SPY: 2 Opposing Forces Wall Street Lunch: Fed Not Spooked By Recent Inflation Overbought conditions flash across all market caps: Bespoke Investment Group Energ...
2024-03-05 16:32:03 ET More on Gritstone bio Gritstone bio: Looking For Validation In 2024 Gritstone to cut 40% of staff due to funding delay, stock plunges 23% Seeking Alpha’s Quant Rating on Gritstone bio Historical earnings data for Gritstone bio ...
-- Preliminary data from Phase 2 portion of Phase 2/3 study evaluating GRANITE, Gritstone’s personalized cancer vaccine in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC) remain expected in 1Q 2024 -- -- National Cancer Institute-led Phase 1 study evaluat...
News, Short Squeeze, Breakout and More Instantly...
Gritstone Oncology Inc. Company Name:
GRTS Stock Symbol:
NASDAQ Market:
Gritstone Oncology Inc. Website:
-- Favorable progression-free survival (PFS) trend observed in preliminary data from the randomized Phase 2 study evaluating GRANITE (personalized neoantigen vaccine) in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC); mature PFS data expected in the third quarter of 2024...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
-- Conference call and webcast to begin at 4:30pm ET -- EMERYVILLE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), ...